RUMORED BUZZ ON BMS-214662

While in the multiday, numerous-dose arm, baseline microbiota was equivalent among topics that obtained ibezapolstat as opposed with vancomycin. At Day 10 of dosing, differential abundance Investigation and β-diversity demonstrated a distinct distinction between the microbiome in topics provided vancomycin as opposed with either dose of ibezapolst